LIPID DISORDERS / RESEARCH PAPER
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The role of triglyceride-rich lipoproteins in atherogenesis is insufficiently recognized and often underestimated. WE aimed to evaluate the distribution of serum triglyceride (TG), remnant cholesterol (RC), and small dense LDL cholesterol (sdLDL-C) levels and their interrelationships in participants of the NATPOL 2011 survey.

Material and methods:
In approximately 2,000 NATPOL participants, serum TG was measured, and serum RC and sdLDL-C were calculated and compared between women and men, across age groups, and in relation to overweight/obesity and plasma glucose. RC/sdLDL-C levels were also compared in the serum TG intervals: <100, 100–149 and 150–499 mg/dL, and their percentile distribution was analyzed.

Results:
Serum TG, RC and sdLDL-C were higher in overweight / obese participants and in those with prediabetes. In subjects with serum TG <100, 100–149 and 150–499 mg/dL, RC and sdLDL-C levels were successively higher, with values adopted as cut-offs for high ASCVD risk observed in both intervals >100 mg/dL. Participants with serum RC and sdLDL-C above these cutoffs had higher TG. Serum TG of 100 mg/dL and 150 mg/dL were the 55.9th and 88.2nd percentile, respectively, serum RC of 24 mg/dL was the 73.8th percentile, and serum sdLDL-C of 30 mg/dL (adopted cut-offs) was the 38th percentile of the distribution results.

Conclusions:
We found an association between serum RC and sdLDL-C, and TG levels >100 mg/dL indicating that serum TG levels of 100–150 mg/dL already represent a state of possible TRL remnants and sdLDL accumulation. Calculated serum RC/sdLDL-C may be considered a useful supplement to the lipid profile.
REFERENCES (40)
1.
Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016; 118: 547-563.
 
2.
Xu D, Xie L, Cheng C et al. Triglyceride-rich lipoproteins and cardiovascular diseases. Front Endocrinol 2024; 15: 1409653.
 
3.
Ginsberg HN, Packard CJ, Chapman MJ et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies - a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021; 42: 4791-4806.
 
4.
Durana EK, Pradhanb AD. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease. Clin Chem 2021; 67: 183-197.
 
5.
Balling M, Afzal S, Varbo A et al. Remnant Cholesterol: Quantification, Concentrations by Sex and Age, and Risk of Ischemic Heart Disease. Clin Chem 2025; 71: 451-462.
 
6.
Zhao Y, Zhuang Z, Li Y et al. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nature Com 2024; 15: 2451.
 
7.
Baratta F, Cocomello N, Coronati M et al. Cholesterol Remnants, Triglyceride-Rich ipoproteins and Cardiovascular Risk. Int J Mol Sci 2023; 24: 4268.
 
8.
Duran EK, Aday AW, Cook NR et al. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. JACC 2020; 75: 1 2 2 - 3 5.
 
9.
Krauss RM. Small Dense LDL Particles: Clinically Relevant? Cur Opin Lipidol 2022; 33: 160-166.
 
10.
Vekic J, Zeljkovic A, Cicero AFG, Janez A et al. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina 2022; 58: 299.
 
11.
Raposeiras-Roubin S, Rossello X, Oliva B et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021; 77: 3031–3041.
 
12.
Solnica B, Sygitowicz G, Sitkiewicz D et al. 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci 2024; 20: 357-374.
 
13.
Sampson M, Wolska A, Warnick R et al. New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem 2021; 67:987-997.
 
14.
Zdrojewski T, Rutkowski M, Bandosz P et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol 2013; 71:381-392.
 
15.
Quispe R, Martin SS, Michos ED et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a pri¬mary prevention study. Eur Heart J. 2021; 42: 4324–4332.
 
16.
Varbo A, Freiberg JJ, Nordestgaard BG. Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. Clin Chem 2018; 64: 1219-230.
 
17.
Doi T, Langsted A, Nordestgaard BG. Elevated Remnant Chole¬sterol Reclassifies Risk of Ischemic Heart Disease and Myocar¬dial Infarction. J Am Coll Cardiol. 2022; 79: 2383–2397.
 
18.
Ikezaki H, Lim E, Cupples LA et al. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc. 2021;10: e019140.
 
19.
Inyaku M, Tanaka M, Sato T et al. Calculated Small Dense Low-Density Lipoprotein Cholesterol Level is A Predominant Predictor for New Onset of Ischemic Heart Disease. J Atheroscler Thromb 2024; 31: 232-248.
 
20.
Koba S, Satoh N, Ito Y et al. Impact of Direct Measurement of Small Dense Low-Density Lipoprotein Cholesterol for Long-Term Secondary Prevention in Patients with Stable Coronary Artery Disease. Clin Chem 2024; 70: 957–966.
 
21.
Toth PP, Banach M. It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease. Eur Heart J Open. 2024;4: oeae057.
 
22.
Makover ME, Surma S, Banach M et al. Eliminating atherosclerotic cardiovascular disease residual risk. Eur Heart J. 2023; 44: 4731-4733.
 
23.
Wu SA, Kersten S, Qi L. Lipoprotein Lipase and Its Regulators: An Unfolding Story. Trends Endocrinol Metab. 2021; 32: 48–61.
 
24.
Moulin P, Dufour R, Averna c M et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis 2018; 275: 265e272.
 
25.
Spitler KM, Davies BSJ. Aging and plasma triglyceride metabolism. J Lipid Res 2020; 61: 1161-1167.
 
26.
Feng L, Nian S, Tong Z et al. Age-related trends in lipid levels: a large-scale cross-sectional study of the general Chinese population. BMJ Open 2020;10: e034226.
 
27.
ZhangID F, Zhang Y, Zhang J et al. Small dense low density lipoprotein predominance in patients with type 2 diabetes mellitus using Mendelian randomization. PLoS ONE 2024;19: e0298070.
 
28.
Li B. Liu Y, Zhou X, Chen L et al. Remnant cholesterol is more positively related to diabetes, prediabetes, and insulin resistance than conventional lipid parameters and lipid ratios: A multicenter, large sample survey. J Diabetes 2024; 16: e13592.
 
29.
Hirano T. Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL‑cholesterol in patients with type 2 diabetes, even when LDL‑C targets are achieved. Diabetol Int 2023; 14: 288-293.
 
30.
Srisawasdi P, Vanavanan S, Rochanawutanon M et al. Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. Clin Biochem 2015; 48: 495-502.
 
31.
Hirano T, Satoh N, Ito Y. Specific Increase in Small Dense Low-Density Lipoprotein-Cholesterol Levels beyond Triglycerides in Patients with Diabetes: Implications for Cardiovascular Risk of MAFLD. J Atheroscler Thromb 2024; 31: 36.
 
32.
Wadstrom BN, Pedersen KM, Wulf AB et al. Elevated remnant cholesterol in atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study. Eur Heart J 2023; 44(Suppl 2).
 
33.
Langlois MR, Nordestgaard BG, Langsted A et al for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM).Joint Consensus Initiative Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2019; aop.
 
34.
Grant JK, Kaufman HW, Martin SS. Extensive Evidence Supports the Martin–Hopkins Equation as the LDL-C Calculation of Choice. Clin Chem 2024; 70: 392_–398.
 
35.
Sampson M, Wolska A, Meeusen JW et al. The Sampson-NIH Equation Is the Preferred Calculation Method for LDL-C. Clini Chem 2024; 70: 399–402.
 
36.
Raja V, Aguiar C, Alsayed N et al. Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis 2023; 383: 117312.
 
37.
Zdrojewski T, Solnica B, Cybulska B et al. Prevalence of lipid abnormalities in land. The NATPOL 2011 survey. Kardiol Pol 2016; 74: 213-23.
 
38.
NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicenter of non-optimal cholesterol. Nature 2020; 582(7810): 73-77.
 
39.
Chen Y, Gue Y, Banach M et al. LIPIDOGRAM Investigators. Phenotypes of Polish primary care patients using hierarchical clustering: Exploring the risk of mortality in the LIPIDOGEN2015 study cohort. Eur J Clin Invest. 2024; 54: e14261.
 
40.
Osadnik T, Nowak D, Osadnik K et al. LIPIDOGRAM Investigators. Association of body mass index and long-term mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies: no obesity paradox? Cardiovasc Diabetol. 2023; 22: 323.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top